### Edgar Filing: WATSON PHARMACEUTICALS INC - Form 3

#### WATSON PHARMACEUTICALS INC

Form 3 July 13, 2007

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

**SECURITIES** 

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

Brunner Patrick G.

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

07/09/2007

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

WATSON PHARMACEUTICALS INC [WPI]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O WATSON LABORATORIES, INC., Â 311

**BONNIE CIRCLE** 

(Street)

10% Owner Director

\_X\_\_ Officer

(Check all applicable)

Other (give title below) (specify below) SVP, Manufacturing Operations 6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

CORONA. CAÂ 92880

(City) (State) (Zip)

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial Ownership

(Instr. 5)

Form: Direct (D) or Indirect (I)

(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** 

4. 5. Conversion Ownership Form of or Exercise

Price of

6. Nature of Indirect Beneficial Ownership

(Instr. 4)

Date

Amount or

Derivative Derivative Security:

(Instr. 5)

Security Direct (D)

### Edgar Filing: WATSON PHARMACEUTICALS INC - Form 3

Shares

or Indirect (I) (Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Â

Director 10% Owner Officer Other

Brunner Patrick G.

C/O WATSON LABORATORIES, INC. 311 BONNIE CIRCLE CORONA, CAÂ 92880

Â SVP, Manufacturing Operations Â

**Signatures** 

Patrick G. 07/12/2007 Brunner

\*\*Signature of Date
Reporting Person

# **Explanation of Responses:**

No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2